Psychologists in Amherst, MA Accepting Medicare
104 Psychologists found. Showing 101 - 104
 Stephen M Klein, PHD Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 664 Main St, Amherst, MA 01002 Phone: 413-253-3211 |
 Dr. Amanda Karen Roberts, PHD Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 441 West St, Amherst, MA 01002 Phone: 413-253-0440 |
David Bache Levit, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 79 South Pleasant Street, Amherst, MA 01002 Phone: 413-253-0624 |
Dr. Jane Lois Kristal, PHD Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 33 Sunset Ave, Amherst, MA 01002 Phone: 413-549-4544 Fax: 802-228-4604 |
News Archive
Labor can be longer for obese pregnant women
It takes obese pregnant women who are given medication to induce labor longer to deliver their babies than women of normal body weight.
Studies evaluate the impact of mobility restrictions during lockdown on air quality in urban areas
Two studies led by María Morales Suárez Varela, group leader of the CIBERESP at the University of Valencia and professor of the Department of Preventive Medicine and Public Health at the academic institution, have evaluated the impact of mobility restrictions on air quality and polluting emissions, in Valencia and in three Italian cities.
New drug-based treatment to promote weight loss in young patients with genetic obesity
In a new study researchers from the Institute for Experimental Pediatric Endocrinology of the Charité - Universitätsmedizin Berlin have successfully treat patients whose obesity is caused by a genetic defect.
TGen to lead first-in-patient clinical trial studies to test novel drugs for glioblastoma
SIn 2012, The Ben & Catherine Ivy Foundation awarded $10 million in grants for two groundbreaking brain cancer research projects at the Translational Genomics Research Institute. One of those projects has officially received the final regulatory approval from University of California, San Francisco, which means patient enrollment for the trial can begin.
Neuralstem announces results from Phase I trial using NSI-566 spinal cord stem cells in treatment of ALS
Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) were published in the peer-reviewed journal, "Annals of Neurology".
› Verified 7 days ago
Clinical Social Workers
Psychologists
Counselors
Dentists
Pharmacists
Occupational Therapists